Skip to content

To evaluate thoracic impedance tomography with PressurePod assisted pressure monitoring port PulmoVista 500 for the accuracy and safety of meaningful gas pressure measurements in patients This was a prospective, multicenter, open-label, completely self-controlled clinical trial

To evaluate thoracic impedance tomography with PressurePod assisted pressure monitoring port PulmoVista 500 for the accuracy and safety of meaningful gas pressure measurements in patients This was a prospective, multicenter, open-label, completely self-controlled clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500103329
Enrollment
Unknown
Registered
2025-05-28
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental group:Simultaneous measurement of clinically significant gas pressures such as airway pressure, esophageal pressure, etc. between test and control instruments using a three-way valve.
Control group (self-control):Simultaneous measurement of clinically significant gas pressures such as airway pressure, esophageal pressure, etc. between test and control instruments using a three-way

Sponsors

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Men and women greater than 18 years old (inclusive); 2) Patients scheduled for gas pressure measurements with balloon catheters; 3) Subjects/their legal guardians who can understand and are willing to follow relevant requirements for the clinical trial agree to sign the ICF. 4) Patients scheduled for mechanically ventilation.

Exclusion criteria

Exclusion criteria: 1) Patients with unstable vital signs; 2) Respiratory obstruction of different causes; 3) Concomitant contraindications for gastrointestinal pressure measurement; 4) Pregnant or lactating women; 5) Subjects combined with other disorders that may affect the scientific integrity of data in this study; 6) Subjects who have received other test drugs or medical devices within 30 days prior to enrollment or 5 half-lives of the test drug, whichever is longer, or who are concurrently participating in the clinical studies of other drugs or medical devices; 7) Other conditions, in the investigator’s judgment, deemed inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Consistence of measurement for Airway Pressure;Consistence of measurement for Esophageal pressure;

Secondary

MeasureTime frame
Consistence of measurement for Gastric pressure;Consistence of measurement for Ptp;

Countries

China

Contacts

Public ContactHongping Qu

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

hongpingqu0412@hotmail.com+86 21 6437 0045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026